癌症研究
胰腺癌
医学
脂质代谢
脂滴
炎症
蓝蛋白
PI3K/AKT/mTOR通路
蛋白激酶B
癌变
胰腺炎
促炎细胞因子
基因敲除
癌症
重编程
肿瘤进展
脂肪酸合酶
内分泌学
作者
Lixia Xiao,Yong Ma,Jian Li,Weiwen Cai,Bo Long,Huinian Zhou,Zuoyi Jiao
标识
DOI:10.1016/j.pan.2026.10.028
摘要
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy closely associated with chronic inflammation. However, the molecular link between persistent inflammatory signaling and lipid metabolic reprogramming during PDAC progression remains incompletely understood. We investigated the role of ubiquitin-conjugating enzyme E2T (UBE2T) in this process. METHODS: The effects of UBE2T were evaluated using cellular functional assays, lipidomic profiling, pathway-rescue experiments, and genetically engineered mouse models under chronic inflammatory conditions. The therapeutic effects of β-1,2,3,4,6-pentagalloylglucose (PGG), previously identified as a pharmacological inhibitor of UBE2T, were further assessed in vitro and in vivo. RESULTS: Inflammatory stimulation increased UBE2T expression, whereas UBE2T depletion suppressed PDAC cell proliferation and motility- and invasion-associated phenotypes. Lipidomic analyses revealed extensive UBE2T-dependent remodeling of pancreatic lipid profiles and reduced lipid accumulation following UBE2T loss. UBE2T depletion decreased AKT phosphorylation, sterol regulatory element-binding protein (SREBP1) nuclear accumulation, and fatty acid synthase (FASN) expression. AKT activation partially rescued these alterations, whereas SREBP1 knockdown or AKT inhibition attenuated UBE2T-induced TG accumulation, supporting the involvement of the AKT/SREBP1/FASN axis. In vivo, UBE2T deficiency alleviated inflammation-associated pancreatic pathological progression and reduced pancreatic lipid accumulation. PGG treatment similarly reduced lesion burden, FASN expression, and pancreatic lipid accumulation, with concomitant attenuation of stromal remodeling. CONCLUSIONS: UBE2T links chronic inflammatory signaling to AKT/SREBP1/FASN-associated lipid metabolic reprogramming during PDAC progression. UBE2T deficiency and PGG treatment attenuated pancreatic pathological progression and lipid metabolic remodeling, supporting UBE2T as a potential therapeutic target for PDAC.
科研通智能强力驱动
Strongly Powered by AbleSci AI